Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Acetaminophen  COVID-19 treatment studies for Acetaminophen  C19 studies: Acetaminophen  Acetaminophen   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -71% Improvement Relative Risk Ventilation -14% ICU admission 40% Oxygen therapy -9% c19early.org/ace Kim et al. Acetaminophen for COVID-19 Prophylaxis Is prophylaxis with acetaminophen beneficial for COVID-19? PSM retrospective 324 patients in South Korea Study compares with NSAIDs, results vs. placebo may differ Higher mortality with acetaminophen (not stat. sig., p=0.34) Kim et al., Int. J. Environmental Research and P.., doi:10.3390/ijerph20053832 Favors acetaminophen Favors NSAIDs
Serious Clinical Outcomes of COVID-19 Related to Acetaminophen or NSAIDs from a Nationwide Population-Based Cohort Study
Kim et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph20053832
Kim et al., Serious Clinical Outcomes of COVID-19 Related to Acetaminophen or NSAIDs from a Nationwide Population-Based.., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph20053832
Feb 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective in South Korea, showing no significant differences in outcomes with acetaminophen use vs. NSAID use. Adherence and dosage are unknown.
risk of death, 71.4% higher, RR 1.71, p = 0.34, treatment 12 of 162 (7.4%), control 7 of 162 (4.3%), propensity score matching.
risk of mechanical ventilation, 14.3% higher, RR 1.14, p = 1.00, treatment 8 of 162 (4.9%), control 7 of 162 (4.3%), propensity score matching.
risk of ICU admission, 40.0% lower, RR 0.60, p = 0.72, treatment 3 of 162 (1.9%), control 5 of 162 (3.1%), NNT 81, propensity score matching.
risk of oxygen therapy, 9.1% higher, RR 1.09, p = 0.87, treatment 24 of 162 (14.8%), control 22 of 162 (13.6%), propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kim et al., 21 Feb 2023, retrospective, South Korea, peer-reviewed, mean age 55.8, 4 authors, this trial compares with another treatment - results may be better when compared to placebo.
Contact: lsceline78@gmail.com (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAcetaminophenAll
Abstract: International Journal of Environmental Research and Public Health Article Serious Clinical Outcomes of COVID-19 Related to Acetaminophen or NSAIDs from a Nationwide Population-Based Cohort Study Jin-Woo Kim 1,† , Siyeong Yoon 2,† , Jongheon Lee 1 1 2 * † Citation: Kim, J.-W.; Yoon, S.; Lee, J.; and Soonchul Lee 2, * Department of Orthopaedic Surgery, Nowon Eulji Medical Center, Eulji University, Seoul 01830, Republic of Korea Department of Orthopaedic Surgery, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam-si 13488, Republic of Korea Correspondence: lsceline78@gmail.com; Tel.: +82-31-780-5289; Fax: +82-31-881-7114 These authors contributed equally to this work. Abstract: Acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) have been widely prescribed to infected patients; however, the safety of them has not been investigated in patients with serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to evaluate the association between the previous use of acetaminophen or NSAIDs and the clinical outcomes of SARS-CoV-2 infection. A nationwide population-based cohort study was conducted using the Korean Health Insurance Review and Assessment Database through propensity score matching (PSM). A total of 25,739 patients aged 20 years and older who tested for SARS-CoV-2 were included from 1 January 2015 to 15 May 2020. The primary endpoint was a positive result for a SARS-CoV-2 test, and the secondary endpoint was serious clinical outcomes of SARS-CoV-2 infection, such as conventional oxygen therapy, admission to the intensive care unit, need for invasive ventilation care, or death. Of 1058 patients, after propensity score matching, 176 acetaminophen users and 162 NSAIDs users were diagnosed with coronavirus disease 2019. After PSM, 162 paired data sets were generated, and the clinical outcomes of the acetaminophen group were not significantly different from those of the NSAIDs group. This suggests that acetaminophen and NSAIDs can be used safely to control symptoms in patients suspected of having SARS-CoV-2. Lee, S. Serious Clinical Outcomes of COVID-19 Related to Acetaminophen or NSAIDs from a Nationwide Keywords: SARS-CoV-2; COVID-19; acetaminophen; NSAIDs Population-Based Cohort Study. Int. J. Environ. Res. Public Health 2023, 20, 3832. https://doi.org/10.3390/ ijerph20053832 Academic Editor: Paul B. Tchounwou Received: 31 December 2022 Revised: 19 February 2023 Accepted: 20 February 2023 Published: 21 February 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit